| Patent application number | Description | Published |
|---|
| 20090215757 | Process for Preparation of High-Purity Meloxicam and Meloxicam Potassium Salt - The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid to yield high-purity meloxicam. | 08-27-2009 |
| 20090281137 | INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS - The present invention is related to new 3,3-disubstituted indol-2-one derivatives of the general Formula (I) | 11-12-2009 |
| 20090306144 | PYRIDINE DERIVATIVES OF ALKYL OXINDOLES AS 5-HT7 RECEPTOR ACTIVE AGENTS - New 3,3-disubstituted indol-2-one derivatives of the general formula (I) | 12-10-2009 |
| 20100274020 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES - The invention relates to a process for the preparation of cyclopropyl benzyl ketone compounds of formula (II) wherein R | 10-28-2010 |
| 20110040093 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATE - The invention relates to a process for the preparation of compounds of general formula (III), wherein R represents fluorine or chlorine atom and X represents chlorine or bromine atom, by halogenation of cyclopropyl benzyl ketone of general formula (II), wherein R represents fluorine or chlorine atom and the halogenation is carried out in the mixture of aqueous hydrogen halide and aqueous hydrogen peroxide in the presence of a water miscible solvent or in the presence of a phase transfer catalyst; or the halogenation is carried out in the mixture of sulfuric acid and an alkali metal salt of aqueous hydrogen halide. The process can be applied preferably on industrial scale. | 02-17-2011 |
| 20120116082 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN SALTS - The present invention relates to a new process for the preparation of rosuvastatin [7-[4-(4-Fluorophenyl)-6-isopropyl-2-(methanesulphonyl-methyl-amino)-pyrimidin-5-yl]-(3R,51S)-dihydroxy-hept-6-enoic acid] of the formula (I) salts formed with bivalent cations, preferably with calcium or zinc ions, characterized in that rosuvastatin tert.-butylammonium salt is reacted with the appropriate bivalent cation, preferably with calcium or zinc ions in a mixture of a water immiscible or slightly miscible organic solvent and water and the formed salt is isolated. | 05-10-2012 |
| 20120178729 | CRYSTALLINE FORM I ROSUVASTATIN ZINC SALT - The present invention relates to crystalline Form I rosuvastatin zinc (2:1) salt, method of preparation thereof and use thereof as pharmaceutically active ingredient for the treatment of diseases related to lipid metabolism including hyperlipoproteinemia, hypercholesteremia, dyslipidemia and atherosclerosis. | 07-12-2012 |
| 20120252784 | 2,3,4-BENZOTHIADIAZEPINE-2,2-DIOXIDE DERIVATIVES - Novel 2,3,4-benzothiadiazepines-2,2-dioxides and processes for the preparation thereof are disclosed. The compounds influence the central nervous system and may be used to treat or prevent Alzheimer's disease, Parkinson's disease or Huntington's disease, senile dementia not of the Alzheimer's type, vascular dementia, post-stroke dementia, Korsakoff's syndrome, Down's syndrome, schizophrenia, panic disorder, post-traumatic stress disorder, anxiety or depression. | 10-04-2012 |
| 20120330018 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS - The object of the present invention is a process for preparing the 2-acetoxy-5-(2-fluor-α-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-tieno[3,2-c]pyridine (prasugrel) of the formula (I). The process starts form crystalline 5-trityl-4,5,6,7-tetrahydro-tieno[3,2-c]pyridine of the formula (VI). Further objects of the present invention are two novel crystalline forms of 5-trityl-4,5,6,7-tetrahydro-tieno[3,2-c]pyridine of the formula (VI) and the use thereof for preparing the compound of the formula (V) and process preparing thereof. | 12-27-2012 |
| 20130005790 | INORGANIC SALT COMPLEXES OF VILDAGLIPTIN - The present invention relates to the use of novel vildagliptin complexes for the manufacture of high purity vildagliptin of Formula I and/or pharmaceutical acceptable salts thereof. Further objects of the present invention are pharmaceutically acceptable complexes of vildagliptin and/or amorphous and crystalline forms, anhydrous forms, amorphous and crystalline hydrates, amorphous and crystalline solvates of the complexes and a process for the preparation thereof. Another object of the present invention is the high purity vildagliptin and pharmaceutically acceptable salts thereof prepared form the vildagliptin complexes of the present invention, a process for the preparation thereof and pharmaceutical compositions containing vildagliptin base, pharmaceutically acceptable salts and/or complexes and use thereof for the treatment of type 2 diabetes (NIDDM). The present invention provides pharmaceutically advantageous high purity vildagliptin complexes. | 01-03-2013 |
| 20130030183 | PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND - The object of the present invention is a one-pot process for preparing the 2-acetoxy-5-(2-fluoro-α-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-tieno[3,2-c]-pyridine (prasugrel) of the formula (I) by reacting the 5,6,7,7a-tetrahydro-4H-tieno[3,2-c]-pyridine-2-on of the formula (II) with 2-bromo-1-cyclopropyl-2-(2-fluorophenyl)-etanone of the formula (III) or with 2-chloro-1-cyclopropyl-2-(2-fluorphenyl)-etanone of the formula (IIIa) and acetylating of the formed compound of the formula (IV), wherein the reaction is carried out in the presence of an organic base with an acetylation agent without isolating the compound of the formula (IV). The coupling and acetylation are carried out in the presence of the same organic base such as triethylamine, N,N-diisopropyl-ethylamine or pyridine. At the end of the process the prasugrel of the formula (I) is purified by recrystallization from an organic solvent or a mixture of solvents. | 01-31-2013 |
| 20130281694 | METHOD FOR PREPARING ROSUVASTATIN SALTS - The present invention is related to methods for the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S,6E)-dihydroxy-hept-6-enoic acid, intermediates thereof and methods for producing said intermediates. | 10-24-2013 |
| 20130296353 | CRYSTALLINE PHARMACEUTICALLY ACTIVE INGREDIENTS - The present invention is related to crystalline forms of rosuvastatin zinc (2:1) salt. The polymorphs are suitable for use as pharmaceutically active ingredients in the treatment of the diseases of the lipid metabolism including hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis. | 11-07-2013 |
| 20130338360 | METHOD FOR THE PREPARATION OF HIGH-PURITY PHARMACEUTICAL INTERMEDIATES - The present invention is related to intermediates useful in the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid and polymorphs of said intermediates, methods for preparation thereof and use thereof. | 12-19-2013 |
| 20140142303 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS - The invention relates to a process for the preparation of 5-chloro-N-({(5-S)-2-oxo3-[4-(3-oxo-morj)holine-4-yl)-phenyl]-1,3-oxazolidine-5-yl}-methyl) thiophen-2-carboxamide having the INN rivaroxaban. The process is characterized by the reactions according to claim | 05-22-2014 |
| 20140155614 | PHARMACEUTICAL INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF - The present invention relates to a process for the preparation of dabigatran etexilate of the formula | 06-05-2014 |
| Patent application number | Description | Published |
|---|
| 20090215757 | Process for Preparation of High-Purity Meloxicam and Meloxicam Potassium Salt - The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid to yield high-purity meloxicam. | 08-27-2009 |
| 20090281137 | INDOL-2-ONE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS, GASTROINTESTINAL DISORDERS AND CARDIOVASCULAR DISORDERS - The present invention is related to new 3,3-disubstituted indol-2-one derivatives of the general Formula (I) | 11-12-2009 |
| 20110040093 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATE - The invention relates to a process for the preparation of compounds of general formula (III), wherein R represents fluorine or chlorine atom and X represents chlorine or bromine atom, by halogenation of cyclopropyl benzyl ketone of general formula (II), wherein R represents fluorine or chlorine atom and the halogenation is carried out in the mixture of aqueous hydrogen halide and aqueous hydrogen peroxide in the presence of a water miscible solvent or in the presence of a phase transfer catalyst; or the halogenation is carried out in the mixture of sulfuric acid and an alkali metal salt of aqueous hydrogen halide. The process can be applied preferably on industrial scale. | 02-17-2011 |
| 20120035162 | PROCESS FOR PREPARATION OF HIGH-PURITY MELOXICAM AND MELOXICAM POTASSIUM SALT - The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid to yield high-purity meloxicam. | 02-09-2012 |
| 20120330018 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS - The object of the present invention is a process for preparing the 2-acetoxy-5-(2-fluor-α-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-tieno[3,2-c]pyridine (prasugrel) of the formula (I). The process starts form crystalline 5-trityl-4,5,6,7-tetrahydro-tieno[3,2-c]pyridine of the formula (VI). Further objects of the present invention are two novel crystalline forms of 5-trityl-4,5,6,7-tetrahydro-tieno[3,2-c]pyridine of the formula (VI) and the use thereof for preparing the compound of the formula (V) and process preparing thereof. | 12-27-2012 |
| 20130030183 | PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND - The object of the present invention is a one-pot process for preparing the 2-acetoxy-5-(2-fluoro-α-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-tieno[3,2-c]-pyridine (prasugrel) of the formula (I) by reacting the 5,6,7,7a-tetrahydro-4H-tieno[3,2-c]-pyridine-2-on of the formula (II) with 2-bromo-1-cyclopropyl-2-(2-fluorophenyl)-etanone of the formula (III) or with 2-chloro-1-cyclopropyl-2-(2-fluorphenyl)-etanone of the formula (IIIa) and acetylating of the formed compound of the formula (IV), wherein the reaction is carried out in the presence of an organic base with an acetylation agent without isolating the compound of the formula (IV). The coupling and acetylation are carried out in the presence of the same organic base such as triethylamine, N,N-diisopropyl-ethylamine or pyridine. At the end of the process the prasugrel of the formula (I) is purified by recrystallization from an organic solvent or a mixture of solvents. | 01-31-2013 |
| Patent application number | Description | Published |
|---|
| 20120063315 | Method for Congestion Avoidance in 4G Networks - This invention aims to avoid and resolve congestions in wireless 4G networks. The method is based on a central self-organizing network (SON) server, which dynamically changes neighbor lists on congested base station and on all base stations in vicinity. The procedure is triggered by measuring relative committed traffic rate and air interface utilization of the base station. When base station enters into congested state, it notifies the SON server. The SON server creates new neighbor lists for all base stations in the vicinity and removes the congested base station from these lists. With new neighbor lists propagated to mobile stations, the latter won't scan and initiate handovers to the congested base station. The SON server additionally creates a new dense neighbor list and changes handover triggers settings of the congested base station. The mobile stations consequently find other handover opportunities and connect to different base stations. As the air interface resources are released, the base station leaves the congested state. | 03-15-2012 |
| 20120064832 | Method for 4G Node Frequency Selection - A method for 4G node frequency selection describes a mechanism for automatically selecting the frequency of a newly installed base station, thereby optimizing the throughput per area unit of the newly installed base station in its predefined vicinity area. The method is based on an iterative calculation approach which combines real-world network and base station measurements information with the nominal specifications of the newly installed base station (antenna diagram, output power) and the location and direction thereof. | 03-15-2012 |
| 20120083279 | Method for Cognitive 4G Neighborhood Selection - A method for cognitive neighbor selection in 4G networks describes a mechanism for automatic self-learning selection of neighboring base stations for the purpose of providing seamless handoffs in a dense deployment of pico and macro base stations. When a 4G network is modified by adding new base stations, the optimum handoff thresholds and advertised base station neighbors are automatically recalculated in a manner that reduces the number of unnecessary handoffs in a dense network with large number of pico and macro base stations. | 04-05-2012 |
| 20130343189 | METHOD FOR CONGESTION AVOIDANCE IN 4G NETWORKS - This invention aims to avoid and resolve congestions in wireless 4G networks. The method is based on a central self-organizing network (SON) server, which dynamically changes neighbor lists on congested base station and on all base stations in vicinity. The procedure is triggered by measuring relative committed traffic rate and air interface utilization of the base station. When base station enters into congested state, it notifies the SON server. The SON server creates new neighbor lists for all base stations in the vicinity and removes the congested base station from these lists. With new neighbor lists propagated to mobile stations, the latter won't scan and initiate handovers to the congested base station. The SON server additionally creates a new dense neighbor list and changes handover triggers settings of the congested base station. The mobile stations consequently find other handover opportunities and connect to different base stations. As the air interface resources are released, the base station leaves the congested state. | 12-26-2013 |
| 20140241445 | Method for providing quality of service in a multiuser orthogonal frequency division multiplex (OFDM) system - A method that provides quality of service in a multiuser orthogonal frequency division multiplex system. The method assures quality of service at application level, which directly affects user's satisfaction with the service for interactive applications, such as web browsing, and real-time applications. The method uses advanced dynamic resource allocation to achieve a common subjective user state and/or dynamic resource allocation to optimize the throughput of the system while increasing the quality of service at application level. The method takes advantages of the information of the instantaneous channel gain and information of the objective technical parameters of the system and applications. With the incorporation of the technical parameters of the system and applications into the subcarrier allocation, the method may provide quality of service at application level, allow explicit control of system resources, ensure fairness in resource allocation and achieve the optimal throughput of the multiuser orthogonal frequency division multiplex system. | 08-28-2014 |
